Brokerages Set Sanofi (NASDAQ:SNY) Target Price at $57.50

Shares of Sanofi (NASDAQ:SNY) have received an average recommendation of “Moderate Buy” from the four brokerages that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $57.50.

Several equities analysts recently weighed in on SNY shares. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th.

Sanofi Stock Down 1.1 %

NASDAQ SNY opened at $47.96 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The stock has a market capitalization of $121.71 billion, a P/E ratio of 24.74, a price-to-earnings-growth ratio of 1.23 and a beta of 0.61. The stock has a fifty day moving average of $52.80 and a 200-day moving average of $52.15.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the business posted $2.55 EPS. On average, equities research analysts forecast that Sanofi will post 4.28 EPS for the current year.

Hedge Funds Weigh In On Sanofi

Institutional investors and hedge funds have recently made changes to their positions in the company. Northwest Investment Counselors LLC bought a new position in Sanofi during the third quarter worth about $29,000. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the second quarter worth about $25,000. Concord Wealth Partners lifted its holdings in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares in the last quarter. Arrow Financial Corp acquired a new position in shares of Sanofi in the 2nd quarter valued at approximately $35,000. Finally, Sunbelt Securities Inc. increased its stake in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.